Black Diamond Therapeutics BDTX 深 沪
等待开盘 02-05 09:30:00 美东时间
2.39
-0.130
-5.16%
华盛通- 最 高2.52
- 今 开2.51
- 成交量 130.63万股
- 最 低 2.30
- 昨 收 2.52
- 总市值 1.36亿
- 52周最高 4.94
- 市盈率 静 --
- 换手率 2.29%
- 52周最低 1.195
- 委 比 -45.78%
- 总股本 5697.49万
- 历史最高 46.25
- 量 比 1.75
- 振 幅 8.73%
- 历史最低 1.18
- 每 手 1
- 风险率 0.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Lowers Price Target to $8
Piper Sandler analyst Kelsey Goodwin maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Overweight and lowers the price target from $9 to $8.
01-17 00:11
Guggenheim Downgrades Black Diamond Therapeutic to Neutral
Guggenheim analyst Brad Canino downgrades Black Diamond Therapeutic (NASDAQ:BDTX) from Buy to Neutral.
2025-12-04 21:48
Black Diamond Therapeutics To Present Results From Phase 2 Clinical Study Of Silevertinib On Dec. 3
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results
2025-12-03 05:02
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Black Diamond Therapeutics will host a webcast on December 3, 2025, at 8:00am ET to present Phase 2 clinical trial results of silevertinib and provide a program update. The webcast will be accessible via the Investors section of their website, www.blackdiamondtherapeutics.com, with a replay available afterward.
2025-12-02 21:01
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
Black Diamond Therapeutic Q3 EPS $(0.15) Beats $(0.23) Estimate
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 35.9 percent. This is a 46.43 percent increase over losses of $(0.28) per
2025-11-06 20:35
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported financial results for Q3 2025, highlighting $135.5 million in cash, sufficient for operations into Q4 2027. The company plans to disclose ORR and preliminary duration data for silevertinib in 1L EGFRm NSCLC later this quarter. R&D expenses decreased to $7.4 million, and net loss was $8.5 million. Black Diamond is seeking partnerships and FDA feedback for silevertinib's development.
2025-11-06 12:30
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
2025-10-17 09:58
Stifel Reinstates Buy on Black Diamond Therapeutic, Announces $8 Price Target
Stifel analyst Laura Prendergast reinstates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and announces $8 price target.
2025-10-16 21:50
